Lesion detection by [89Zr]Zr-DFO-girentuximab and [18F]FDG-PET/CT in patients with newly diagnosed metastatic renal cell carcinoma.

MLA

Verhoeff, Sarah R., et al. “Lesion Detection by [89Zr]Zr-DFO-Girentuximab and [18F]FDG-PET/CT in Patients with Newly Diagnosed Metastatic Renal Cell Carcinoma.” European Journal of Nuclear Medicine & Molecular Imaging, vol. 46, no. 9, Aug. 2019, pp. 1931–39. EBSCOhost, https://doi.org/10.1007/s00259-019-04358-9.

APA

Verhoeff, S. R., van Es, S. C., Boon, E., van Helden, E., Angus, L., Elias, S. G., Oosting, S. F., Aarntzen, E. H., Brouwers, A. H., Kwee, T. C., Heskamp, S., Hoekstra, O. S., Verheul, H., van der Veldt, A. A. M., de Vries, E. G. E., Boerman, O. C., van der Graaf, W. T. A., Oyen, W. J. G., & van Herpen, C. M. L. (2019). Lesion detection by [89Zr]Zr-DFO-girentuximab and [18F]FDG-PET/CT in patients with newly diagnosed metastatic renal cell carcinoma. European Journal of Nuclear Medicine & Molecular Imaging, 46(9), 1931–1939. https://doi.org/10.1007/s00259-019-04358-9

Chicago

Verhoeff, Sarah R., Suzanne C. van Es, Eline Boon, Erik van Helden, Lindsay Angus, Sjoerd G. Elias, Sjoukje F. Oosting, et al. 2019. “Lesion Detection by [89Zr]Zr-DFO-Girentuximab and [18F]FDG-PET/CT in Patients with Newly Diagnosed Metastatic Renal Cell Carcinoma.” European Journal of Nuclear Medicine & Molecular Imaging 46 (9): 1931–39. doi:10.1007/s00259-019-04358-9.